WHO has expressed concern over the health implication of Gilead Science Inc's recently approved remdesivir vaccine.
Remdesivir has become the first drug to obtain formal clearance for treating the coronavirus disease.
The study found that the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course.
The agreements with the 2 drug firms follow requests by EU countries in May.
The WHO boss had earlier warned that the worst is yet to come from the coronavirus pandemic.
After making the announcement on Monday, Gilead’s share price jumped up 2.7% to in premarket trading.
The experimental drug produced by Gilead Sciences Inc seems to be taking a step closer to the much-needed cure for patients infected with Coronavirus.